Stellar Biotechnologies
Port Hueneme Cbc Base
About Stellar Biotechnologies
Stellar Biotechnologies, Inc. is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccine pipelines (targeting cancers, immune disorders, Alzheimer's and inflammatory diseases) and for assessing immune system function. KLH can also be used in immunotoxicology studies for monitoring the immunomodulatory effects of drug candidates.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $46.7M
- Funding stage: M&A
- Last round: Post-IPO Equity (Mar 2021)
- Ticker: nasdaq:SBOT
- Website: stellarklh.com
- Phone: 8054882147
Industries & Categories
Biotechnology, Health Diagnostics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/stellar-biotechnologies-182696 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.